BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-1.13%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$5.86B
AUM Growth
+$5.86B
(+222%)
Cap. Flow
+$4.03B
Cap. Flow
% of AUM
68.76%
Top 10 Holdings %
Top 10 Hldgs %
42.44%
Holding
219
New
83
Increased
86
Reduced
22
Closed
16
Top Buys
| 1 |
Ionis Pharmaceuticals
IONS
|
$492M |
| 2 |
Incyte
INCY
|
$310M |
| 3 |
Neurocrine Biosciences
NBIX
|
$298M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$239M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$239M |
Top Sells
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
$29.2M |
| 2 |
Cencora
COR
|
$19.9M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
$16.5M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
$14.7M |
| 5 |
Illumina
ILMN
|
$10.9M |
Sector Composition
| 1 | Healthcare | 94.72% |
| 2 | Technology | 0.56% |
| 3 | Industrials | 0.42% |
| 4 | Financials | 0.06% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ionis Pharmaceuticals
IONS
$6.8B
| $511M | 8.73% | 7,957,128 +7,654,485 | +2,529% | +$492M |
|
|
2
Incyte
INCY
$16.5B
| $314M | 5.36% | 3,697,650 +3,649,150 | +7,524% | +$310M |
|
|
3
Neurocrine Biosciences
NBIX
$13.8B
| $299M | 5.11% | 3,546,444 +3,526,244 | +17,457% | +$298M |
|
|
4
Vertex Pharmaceuticals
VRTX
$100B
| $260M | 4.45% | 1,420,489 +1,303,500 | +1,114% | +$239M |
|
|
SAGE
5
DELISTED
Sage Therapeutics
SAGE
| $242M | 4.13% | 1,321,404 +1,305,104 | +8,007% | +$239M |
|
6
Esperion Therapeutics
ESPR
$448M
| $189M | 3.22% | 4,057,411 +3,561,864 | +719% | +$166M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $176M | 3% | 1,341,428 +1,170,278 | +684% | +$153M |
|
|
CELG
8
DELISTED
Celgene Corp
CELG
| $171M | 2.92% | 1,850,000 +1,832,212 | +10,300% | +$169M |
|
|
RDUS
9
DELISTED
Radius Health, Inc.
RDUS
| $167M | 2.85% | 6,840,785 +6,781,685 | +11,475% | +$165M |
|
10
Agios Pharmaceuticals
AGIO
$2.19B
| $156M | 2.66% | +3,128,134 | New | +$156M |
|
11
Halozyme
HALO
$8.56B
| $142M | 2.42% | +8,247,860 | New | +$142M |
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $140M | 2.39% | 1,927,394 +1,660,089 | +621% | +$120M |
|
13
argenx
ARGX
$43.6B
| $134M | 2.28% | 944,639 +924,739 | +4,647% | +$131M |
|
14
Elevance Health
ELV
$71.8B
| $102M | 1.74% | 360,739 +105,722 | +41% | +$29.8M |
|
15
Teladoc Health
TDOC
$1.37B
| $95.3M | 1.63% | 1,435,012 +60,718 | +4% | +$4.03M |
|
16
Nektar Therapeutics
NKTR
$568M
| $93.7M | 1.6% | 2,632,686 +2,202,660 | +512% | +$78.4M |
|
17
Intuitive Surgical
ISRG
$170B
| $88.4M | 1.51% | 168,482 +17,483 | +12% | +$9.17M |
|
|
18
Illumina
ILMN
$15.8B
| $84M | 1.43% | 228,191 -29,505 | -11% | -$10.9M |
|
19
Align Technology
ALGN
$10.3B
| $83.9M | 1.43% | 306,595 -28,084 | -8% | -$7.69M |
|
20
Exelixis
EXEL
$10.1B
| $82.9M | 1.42% | 3,878,800 +3,738,300 | +2,661% | +$79.9M |
|
21
Abbott
ABT
$231B
| $80.5M | 1.38% | 957,595 -82,992 | -8% | -$6.98M |
|
22
Medtronic
MDT
$119B
| $75.9M | 1.3% | 779,411 +288,505 | +59% | +$28.1M |
|
23
MacroGenics
MGNX
$112M
| $74.6M | 1.27% | 4,395,264 +3,604,959 | +456% | +$61.2M |
|
24
Voyager Therapeutics
VYGR
$186M
| $73M | 1.25% | +2,680,283 | New | +$73M |
|
|
AKCA
25
DELISTED
Akcea Therapeutics, Inc. Common Stock
AKCA
| $72.7M | 1.24% | 3,100,768 +2,596,357 | +515% | +$60.9M |
|